Literature DB >> 24296572

Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Jonathan J Hunt1, Jimmy D Ballard.   

Abstract

Clostridium difficile is a Gram-positive, spore-forming organism which infects and colonizes the large intestine, produces potent toxins, triggers inflammation, and causes significant systemic complications. Treating C. difficile infection (CDI) has always been difficult, because the disease is both caused and resolved by antibiotic treatment. For three and a half decades, C. difficile has presented a treatment challenge to clinicians, and the situation took a turn for the worse about 10 years ago. An increase in epidemic outbreaks related to CDI was first noticed around 2003, and these outbreaks correlated with a sudden increase in the mortality rate of this illness. Further studies discovered that these changes in CDI epidemiology were associated with the rapid emergence of hypervirulent strains of C. difficile, now collectively referred to as NAP1/BI/027 strains. The discovery of new epidemic strains of C. difficile has provided a unique opportunity for retrospective and prospective studies that have sought to understand how these strains have essentially replaced more historical strains as a major cause of CDI. Moreover, detailed studies on the pathogenesis of NAP1/BI/027 strains are leading to new hypotheses on how this emerging strain causes severe disease and is more commonly associated with epidemics. In this review, we provide an overview of CDI, discuss critical mechanisms of C. difficile virulence, and explain how differences in virulence-associated factors between historical and newly emerging strains might explain the hypervirulence exhibited by this pathogen during the past decade.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24296572      PMCID: PMC3973386          DOI: 10.1128/MMBR.00017-13

Source DB:  PubMed          Journal:  Microbiol Mol Biol Rev        ISSN: 1092-2172            Impact factor:   11.056


  195 in total

1.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

2.  Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B.

Authors:  Selda Genisyuerek; Panagiotis Papatheodorou; Gregor Guttenberg; Rolf Schubert; Roland Benz; Klaus Aktories
Journal:  Mol Microbiol       Date:  2011-01-28       Impact factor: 3.501

3.  Fatal Clostridium difficile enteritis after total abdominal colectomy.

Authors:  V A Parikh; J W Edlund
Journal:  J Clin Gastroenterol       Date:  1996-06       Impact factor: 3.062

4.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

5.  Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.

Authors:  S Johnson; S A Kent; K J O'Leary; M M Merrigan; S P Sambol; L R Peterson; D N Gerding
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

6.  Risk factors for Clostridium difficile infection.

Authors:  G E Bignardi
Journal:  J Hosp Infect       Date:  1998-09       Impact factor: 3.926

7.  The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.

Authors:  I Just; M Wilm; J Selzer; G Rex; C von Eichel-Streiber; M Mann; K Aktories
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

8.  A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates.

Authors:  M Rupnik; V Avesani; M Janc; C von Eichel-Streiber; M Delmée
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

9.  Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Authors:  Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

10.  Binary toxin and death after Clostridium difficile infection.

Authors:  Sabrina Bacci; Kåre Mølbak; Marianne K Kjeldsen; Katharina E P Olsen
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

View more
  40 in total

1.  Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection.

Authors:  Michael C Abt; Brittany B Lewis; Silvia Caballero; Huizhong Xiong; Rebecca A Carter; Bože Sušac; Lilan Ling; Ingrid Leiner; Eric G Pamer
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

2.  Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype.

Authors:  Rossella Baldan; Alberto Trovato; Valentina Bianchini; Anna Biancardi; Paola Cichero; Maria Mazzotti; Paola Nizzero; Matteo Moro; Cristina Ossi; Paolo Scarpellini; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

Review 3.  Laboratory diagnosis of bacterial gastroenteritis.

Authors:  Romney M Humphries; Andrea J Linscott
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

4.  Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.

Authors:  S Mani; L Rybicki; D Jagadeesh; S B Mossad
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

5.  Clostridioides difficile SinR' regulates toxin, sporulation and motility through protein-protein interaction with SinR.

Authors:  Yusuf Ciftci; Brintha Parasumanna Girinathan; Babita Adhikari Dhungel; Md Kamrul Hasan; Revathi Govind
Journal:  Anaerobe       Date:  2019-05-08       Impact factor: 3.331

Review 6.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

7.  Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.

Authors:  Ilana L Stroke; Jeffrey J Letourneau; Teresa E Miller; Yan Xu; Igor Pechik; Diana R Savoly; Linh Ma; Laurie J Sturzenbecker; Joan Sabalski; Philip D Stein; Maria L Webb; David W Hilbert
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Protein expression, characterization, crystallization and preliminary X-ray crystallographic analysis of a Fic protein from Clostridium difficile.

Authors:  Ditte Welner; Emil Dedic; Hans C van Leeuwen; Ed Kuijper; Morten Jannik Bjerrum; Ole Østergaard; René Jørgensen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-05-25       Impact factor: 1.056

Review 9.  Structural insight into Wnt signaling inhibition by Clostridium difficile toxin B.

Authors:  Peng Chen; Liang Tao; Zheng Liu; Min Dong; Rongsheng Jin
Journal:  FEBS J       Date:  2018-11-01       Impact factor: 5.542

10.  Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.

Authors:  Jenessa A Winston; Alissa J Rivera; Jingwei Cai; Rajani Thanissery; Stephanie A Montgomery; Andrew D Patterson; Casey M Theriot
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.